{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T21:08:31Z","timestamp":1788815311497,"version":"build-2803163510"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Psychiatry Research"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.psychres.2026.117395","type":"journal-article","created":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T14:53:22Z","timestamp":1786805602000},"page":"117395","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Drug-specific and developmental heterogeneity in adverse event profiles of atypical antipsychotics in the pediatric population: A FAERS pharmacovigilance study"],"prefix":"10.1016","volume":"365","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-1641-3055","authenticated-orcid":false,"given":"Chenjin","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingying","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxiao","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zilun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongyi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meirong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"22","key":"10.1016\/j.psychres.2026.117395_bib0001","doi-asserted-by":"crossref","first-page":"7942","DOI":"10.3390\/jcm14227942","article-title":"Metabolic and endocrine ADRs of Atypical antipsychotics (AAPs) in paediatric patients with autism spectrum disorder (ASD): a review of prevalence, risk factors, and implications for clinical monitoring","volume":"14","author":"Aljead","year":"2025","journal-title":"J. Clin. Med."},{"issue":"3","key":"10.1016\/j.psychres.2026.117395_bib0002","article-title":"Trends and prevalence of psychotropic medication use in children and adolescents in the period between 2013 and 2023: a systematic review","volume":"16","author":"Altuwairqi","year":"2024","journal-title":"Cureus"},{"issue":"3","key":"10.1016\/j.psychres.2026.117395_bib0003","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1056\/NEJM199307153290303","article-title":"Clozapine-induced agranulocytosis. Incidence and risk factors in the United States","volume":"329","author":"Alvir","year":"1993","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.psychres.2026.117395_bib0004","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s002280050466","article-title":"A Bayesian neural network method for adverse drug reaction signal generation","volume":"54","author":"Bate","year":"1998","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"2","key":"10.1016\/j.psychres.2026.117395_bib0005","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s40268-015-0092-x","article-title":"Comparative pharmacology of risperidone and paliperidone","volume":"15","author":"Corena-McLeod","year":"2015","journal-title":"Drugs R. D."},{"issue":"1","key":"10.1016\/j.psychres.2026.117395_bib0006","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/chi.0b013e31815b5cb1","article-title":"Antipsychotic use in children and adolescents: minimizing adverse effects to maximize outcomes","volume":"47","author":"Correll","year":"2008","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"issue":"16","key":"10.1016\/j.psychres.2026.117395_bib0007","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1001\/jama.2009.1549","article-title":"Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents","volume":"302","author":"Correll","year":"2009","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.psychres.2026.117395_bib0008","doi-asserted-by":"crossref","first-page":"w770","DOI":"10.1377\/hlthaff.28.5.w770","article-title":"Broadened use of atypical antipsychotics: safety, effectiveness, and policy challenges","volume":"28","author":"Crystal","year":"2009","journal-title":"Health Aff. (Millwood)"},{"key":"10.1016\/j.psychres.2026.117395_bib0009","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/656370","article-title":"Second-generation antipsychotics and extrapyramidal adverse effects","author":"Divac","year":"2014","journal-title":"Biomed. Res. Int."},{"issue":"3","key":"10.1016\/j.psychres.2026.117395_bib0010","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1080\/00031305.1999.10474456","article-title":"Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system","volume":"53","author":"Dumouchel","year":"1999","journal-title":"Am. Stat."},{"key":"10.1016\/j.psychres.2026.117395_bib0011","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jad.2024.02.038","article-title":"Sex differences in effectiveness and adverse effects of mood stabilizers and antipsychotics: a systematic review","volume":"352","author":"Ercis","year":"2024","journal-title":"J. Affect. Disord."},{"issue":"6","key":"10.1016\/j.psychres.2026.117395_bib0012","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol. Drug Saf."},{"issue":"20","key":"10.1016\/j.psychres.2026.117395_bib0013","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.2165\/00003495-200464200-00003","article-title":"Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management","volume":"64","author":"Haddad","year":"2004","journal-title":"Drugs"},{"issue":"5","key":"10.1016\/j.psychres.2026.117395_bib0014","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2165\/00002018-200629050-00003","article-title":"Under-reporting of adverse drug reactions : a systematic review","volume":"29","author":"Hazell","year":"2006","journal-title":"Drug Saf."},{"issue":"1","key":"10.1016\/j.psychres.2026.117395_bib0015","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s40360-024-00782-2","article-title":"Drug-induced liver injury associated with atypical generation antipsychotics from the FDA adverse event reporting system (FAERS)","volume":"25","author":"He","year":"2024","journal-title":"BMC Pharmacol. Toxicol."},{"issue":"3","key":"10.1016\/j.psychres.2026.117395_bib0016","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/sj.npp.1300027","article-title":"H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs","volume":"28","author":"Kroeze","year":"2003","journal-title":"Neuropsychopharmacology"},{"issue":"7","key":"10.1016\/j.psychres.2026.117395_bib0017","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1089\/cap.2021.0140","article-title":"A meta-analysis of antipsychotic-induced hypo- and hyperprolactinemia in children and adolescents","volume":"32","author":"Kr\u00f8igaard","year":"2022","journal-title":"J. Child Adolesc. Psychopharmacol."},{"issue":"9657","key":"10.1016\/j.psychres.2026.117395_bib0018","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)61764-X","article-title":"Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis","volume":"373","author":"Leucht","year":"2009","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.psychres.2026.117395_bib0019","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1097\/JS9.0000000000002194","article-title":"Systematic analysis of sugammadex-related adverse drug reaction signals using FAERS database","volume":"111","author":"Liu","year":"2025","journal-title":"Int. J. Surg."},{"issue":"6","key":"10.1016\/j.psychres.2026.117395_bib0020","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.jaac.2017.03.013","article-title":"What is the male-to-female ratio in autism spectrum disorder? A Systematic Review and Meta-Analysis","volume":"56","author":"Loomes","year":"2017","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"key":"10.1016\/j.psychres.2026.117395_bib0021","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1146\/annurev-med-050911-161504","article-title":"Update on typical and atypical antipsychotic drugs","volume":"64","author":"Meltzer","year":"2013","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.psychres.2026.117395_bib0022","article-title":"Dopamine receptor partial agonists: do they differ in their clinical efficacy?","volume":"12","author":"Mohr","year":"2021","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.psychres.2026.117395_bib0023","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2024.1322939","article-title":"Characteristics of eye disorders induced by atypical antipsychotics: a real-world study from 2016 to 2022 based on food and drug administration adverse event reporting system","volume":"15","author":"Mu","year":"2024","journal-title":"Front. Psychiatry"},{"issue":"12","key":"10.1016\/j.psychres.2026.117395_bib0024","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1001\/archgenpsychiatry.2012.647","article-title":"National trends in the office-based treatment of children, adolescents, and adults with antipsychotics","volume":"69","author":"Olfson","year":"2012","journal-title":"Arch. Gen. Psychiatry"},{"issue":"9","key":"10.1016\/j.psychres.2026.117395_bib0025","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1001\/jamapsychiatry.2015.0500","article-title":"Treatment of young people with antipsychotic medications in the United States","volume":"72","author":"Olfson","year":"2015","journal-title":"JAMA Psychiatry"},{"issue":"6","key":"10.1016\/j.psychres.2026.117395_bib0026","doi-asserted-by":"crossref","DOI":"10.3346\/jkms.2026.41.e53","article-title":"Trends in atypical antipsychotic use among children and adolescents with depressive disorders in Korea","volume":"41","author":"Park","year":"2026","journal-title":"J. Korean Med. Sci."},{"issue":"6","key":"10.1016\/j.psychres.2026.117395_bib0027","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s40264-020-00928-1","article-title":"A disproportionality analysis of the adverse drug events associated with lurasidone in paediatric patients using the US FDA adverse event reporting System (FAERS)","volume":"43","author":"Rees","year":"2020","journal-title":"Drug Saf."},{"issue":"1","key":"10.1016\/j.psychres.2026.117395_bib0028","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.pharmthera.2009.10.010","article-title":"Metabolic side effects of antipsychotic drug treatment\u2013pharmacological mechanisms","volume":"125","author":"Reynolds","year":"2010","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.psychres.2026.117395_bib0029","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.889088","article-title":"Generalised weibull model-based approaches to detect non-constant hazard to signal adverse drug reactions in longitudinal data","volume":"13","author":"Sauzet","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"5","key":"10.1016\/j.psychres.2026.117395_bib0030","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1093\/schbul\/sbn023","article-title":"Secondary effects of antipsychotics: women at greater risk than men","volume":"35","author":"Seeman","year":"2009","journal-title":"Schizophr. Bull."},{"issue":"1","key":"10.1016\/j.psychres.2026.117395_bib0031","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/s41380-021-01161-7","article-title":"Age at onset of mental disorders worldwide: large-scale meta-analysis of 192 epidemiological studies","volume":"27","author":"Solmi","year":"2022","journal-title":"Mol. Psychiatry"},{"issue":"3","key":"10.1016\/j.psychres.2026.117395_bib0032","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/wps.20567","article-title":"Management of common adverse effects of antipsychotic medications","volume":"17","author":"Stroup","year":"2018","journal-title":"World Psychiatry"},{"issue":"1","key":"10.1016\/j.psychres.2026.117395_bib0033","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/pds.668","article-title":"A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions","volume":"11","author":"van Puijenbroek","year":"2002","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.psychres.2026.117395_bib0034","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1438292","article-title":"Adverse drug reaction signals mining comparison of amiodarone and dronedarone: a pharmacovigilance study based on FAERS","volume":"15","author":"Xu","year":"2024","journal-title":"Front. Pharmacol."},{"issue":"4","key":"10.1016\/j.psychres.2026.117395_bib0035","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1080\/17425255.2023.2219390","article-title":"A real-world data analysis of topotecan in the FDA adverse event reporting system (FAERS) database","volume":"19","author":"Yang","year":"2023","journal-title":"Expert. Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.psychres.2026.117395_bib0036","article-title":"Thromboembolic events with olanzapine: a systematic review integrating meta-analysis and FAERS database","volume":"13","author":"Zhang","year":"2026","journal-title":"Front. Cardiovasc. Med."},{"key":"10.1016\/j.psychres.2026.117395_bib0037","article-title":"A real-world disproportionality analysis of Everolimus: data mining of the public version of FDA adverse event reporting system","volume":"15","author":"Zhao","year":"2024","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.psychres.2026.117395_bib0038","doi-asserted-by":"crossref","first-page":"4104","DOI":"10.1038\/s41598-025-88838-z","article-title":"Analysis of ADR reports of cetuximab based on the FDA adverse event reporting system database","volume":"15","author":"Zhao","year":"2025","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.psychres.2026.117395_bib0039","doi-asserted-by":"crossref","DOI":"10.31083\/AP44501","article-title":"Seizures risk related to atypical antipsychotics: a disproportionality analysis based on the FDA adverse event reporting system (FAERS)","volume":"27","author":"Zhao","year":"2026","journal-title":"Alpha Psychiat."},{"issue":"Pt B","key":"10.1016\/j.psychres.2026.117395_bib0040","article-title":"Glucose dysregulation signals in weight-neutral atypical antipsychotics: a pharmacovigilance-pharmacodynamic evaluation of FAERS data","volume":"393","author":"Zheng","year":"2026","journal-title":"J. Affect. Disord."},{"issue":"11","key":"10.1016\/j.psychres.2026.117395_bib0041","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1080\/14740338.2024.2410436","article-title":"A real-world pharmacovigilance study using disproportionality analysis of United States Food and Drug Administration Adverse Event Reporting System events for vinca alkaloids: comparing vinorelbine and vincristine","volume":"23","author":"Zhong","year":"2024","journal-title":"Expert. Opin. Drug Saf."}],"container-title":["Psychiatry Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178126004555?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178126004555?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T20:25:25Z","timestamp":1788812725000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165178126004555"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":41,"alternative-id":["S0165178126004555"],"URL":"https:\/\/doi.org\/10.1016\/j.psychres.2026.117395","relation":{},"ISSN":["0165-1781"],"issn-type":[{"value":"0165-1781","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug-specific and developmental heterogeneity in adverse event profiles of atypical antipsychotics in the pediatric population: A FAERS pharmacovigilance study","name":"articletitle","label":"Article Title"},{"value":"Psychiatry Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.psychres.2026.117395","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117395"}}